Blood-pressure and cholesterol lowering in persons without cardiovascular disease
Elevated blood pressure and elevated low-density lipoprotein (LDL) cholesterol increase the risk of cardiovascular disease. Lowering both should reduce the risk of cardiovascular events substantially. In a trial with 2-by-2 factorial design, we randomly assigned 12,705 participants at intermed...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English English English |
| Published: |
Massachusetts Medical Society
2016
|
| Subjects: | |
| Online Access: | http://irep.iium.edu.my/50347/ http://irep.iium.edu.my/50347/ http://irep.iium.edu.my/50347/ http://irep.iium.edu.my/50347/9/Dr_Aznan_Blood-Pressure_and_Cholesterol_Lowering.pdf http://irep.iium.edu.my/50347/12/nejmoa1600177_appendix.pdf http://irep.iium.edu.my/50347/13/50347_Blood-Pressure_and_Cholesterol_Lowering_wos_scopus.pdf |
| Summary: | Elevated blood pressure and elevated low-density lipoprotein (LDL) cholesterol
increase the risk of cardiovascular disease. Lowering both should reduce the risk
of cardiovascular events substantially.
In a trial with 2-by-2 factorial design, we randomly assigned 12,705 participants at
intermediate risk who did not have cardiovascular disease to rosuvastatin (10 mg per
day) or placebo and to candesartan (16 mg per day) plus hydrochlorothiazide (12.5 mg
per day) or placebo. In the analyses reported here, we compared the 3180 participants
assigned to combined therapy (with rosuvastatin and the two antihypertensive agents)
with the 3168 participants assigned to dual placebo. The first coprimary outcome was
the composite of death from cardiovascular causes, nonfatal myocardial infarction, or
nonfatal stroke, and the second coprimary outcome additionally included heart failure,
cardiac arrest, or revascularization. The median follow-up was 5.6 years. |
|---|